Literature DB >> 25751641

Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Xiao Zhang1, Lu Xin, Shaowei Li, Mujin Fang, Jun Zhang, Ningshao Xia, Qinjian Zhao.   

Abstract

Recombinant VLP-based vaccines have been successfully used against 3 diseases caused by viral infections: Hepatitis B, cervical cancer and hepatitis E. The VLP approach is attracting increasing attention in vaccine design and development for human and veterinary use. This review summarizes the clinically relevant epitopes on the VLP antigens in successful human vaccines. These virion-like epitopes, which can be delineated with molecular biology, cryo-electron microscopy and x-ray crystallographic methods, are the prerequisites for these efficacious vaccines to elicit functional antibodies. The critical epitopes and key factors influencing these epitopes are discussed for the HEV, HPV and HBV vaccines. A pentamer (for HPV) or a dimer (for HEV and HBV), rather than a monomer, is the basic building block harboring critical epitopes for the assembly of VLP antigen. The processing and formulation of VLP-based vaccines need to be developed to promote the formation and stabilization of these epitopes in the recombinant antigens. Delineating the critical epitopes is essential for antigen design in the early phase of vaccine development and for critical quality attribute analysis in the commercial phase of vaccine manufacturing.

Entities:  

Keywords:  capsid protein; conformation-dependent epitope; human vaccine; immunodominant epitopes; neutralizing antibodies; virus-like particle

Mesh:

Substances:

Year:  2015        PMID: 25751641      PMCID: PMC4514273          DOI: 10.1080/21645515.2015.1016675

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  157 in total

1.  HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.

Authors:  S W Ludmerer; W L McClements; X M Wang; J C Ling; K U Jansen; N D Christensen
Journal:  Virology       Date:  2000-01-20       Impact factor: 3.616

2.  Study of infectious virus production from HPV18/16 capsid chimeras.

Authors:  Horng-Shen Chen; Jennifer Bromberg-White; Michael J Conway; Samina Alam; Craig Meyers
Journal:  Virology       Date:  2010-07-03       Impact factor: 3.616

3.  Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.

Authors:  W I White; S D Wilson; F J Palmer-Hill; R M Woods; S J Ghim; L A Hewitt; D M Goldman; S J Burke; A B Jenson; S Koenig; J A Suzich
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Authors:  Nubia Muñoz; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricía J Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Warner K Huh; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret K James; Teresa M Hesley; Eliav Barr; Richard M Haupt
Journal:  J Natl Cancer Inst       Date:  2010-02-05       Impact factor: 13.506

5.  Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution.

Authors:  F P Booy; R B Roden; H L Greenstone; J T Schiller; B L Trus
Journal:  J Mol Biol       Date:  1998-08-07       Impact factor: 5.469

6.  Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts.

Authors:  Chunyan Yang; Huirong Pan; Minxi Wei; Xiao Zhang; Nan Wang; Ying Gu; Hailian Du; Jun Zhang; Shaowei Li; Ningshao Xia
Journal:  Protein Sci       Date:  2013-01-17       Impact factor: 6.725

7.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

Authors:  R C Rose; R C Reichman; W Bonnez
Journal:  J Gen Virol       Date:  1994-08       Impact factor: 3.891

Review 8.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

9.  Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata.

Authors:  J W Kreider; M K Howett; S A Wolfe; G L Bartlett; R J Zaino; T Sedlacek; R Mortel
Journal:  Nature       Date:  1985 Oct 17-23       Impact factor: 49.962

10.  Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.

Authors:  Qinjian Zhao; Yorgo Modis; Katrina High; Victoria Towne; Yuan Meng; Yang Wang; Jaime Alexandroff; Martha Brown; Bridget Carragher; Clinton S Potter; Dicky Abraham; Dave Wohlpart; Mike Kosinski; Mike W Washabaugh; Robert D Sitrin
Journal:  Virol J       Date:  2012-02-22       Impact factor: 4.099

View more
  13 in total

1.  Engineering a Virus-like Particle to Display Peptide Insertions Using an Apparent Fitness Landscape.

Authors:  Stephanie A Robinson; Emily C Hartman; Bon C Ikwuagwu; Matthew B Francis; Danielle Tullman-Ercek
Journal:  Biomacromolecules       Date:  2020-09-03       Impact factor: 6.988

2.  Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent.

Authors:  Bin He; Zhigang Zhang; Xinyuan Zhang; Zimin Tang; Chang Liu; Zizheng Zheng; Shaowei Li; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

Review 3.  Recent trends and advances in microbe-based drug delivery systems.

Authors:  Pravin Shende; Vasavi Basarkar
Journal:  Daru       Date:  2019-08-02       Impact factor: 3.117

4.  Biodegradable Viral Nanoparticle/Polymer Implants Prepared via Melt-Processing.

Authors:  Parker W Lee; Sourabh Shukla; Jaqueline D Wallat; Chaitanya Danda; Nicole F Steinmetz; Joao Maia; Jonathan K Pokorski
Journal:  ACS Nano       Date:  2017-09-13       Impact factor: 15.881

Review 5.  Hepatitis E virus: Current epidemiology and vaccine.

Authors:  Xing Wu; Pan Chen; Huijuan Lin; Xiaotian Hao; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452

6.  A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5.

Authors:  Lin Xia; Yangfei Xian; Daning Wang; Yuanzhi Chen; Xiaofen Huang; Xingjian Bi; Hai Yu; Zheng Fu; Xinlin Liu; Shaowei Li; Zhiqiang An; Wenxin Luo; Qinjian Zhao; Ningshao Xia
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

7.  The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.

Authors:  Sara L Bissett; Anna Godi; Simon Beddows
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

8.  Escherichia coli-derived virus-like particles in vaccine development.

Authors:  Xiaofen Huang; Xin Wang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  NPJ Vaccines       Date:  2017-02-09       Impact factor: 7.344

9.  Effects of mRNA secondary structure on the expression of HEV ORF2 proteins in Escherichia coli.

Authors:  Nouredine Behloul; Wenjuan Wei; Sarra Baha; Zhenzhen Liu; Jiyue Wen; Jihong Meng
Journal:  Microb Cell Fact       Date:  2017-11-14       Impact factor: 5.328

10.  A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A.

Authors:  Marco Tamborrini; Nina Geib; Aniebrys Marrero-Nodarse; Maja Jud; Julia Hauser; Celestine Aho; Araceli Lamelas; Armando Zuniga; Gerd Pluschke; Arin Ghasparian; John A Robinson
Journal:  Vaccines (Basel)       Date:  2015-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.